Cargando…
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial
INTRODUCTION: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%. Expression of the triggering receptor expressed on myeloid cells 1 (TREM-1) pathway, measured usin...
Autores principales: | Francois, Bruno, Lambden, Simon, Gibot, Sebastien, Derive, Marc, Olivier, Aurelie, Cuvier, Valerie, Witte, Stephan, Grouin, Jean-Marie, Garaud, Jean Jacques, Salcedo-Magguilli, Margarita, Levy, Mitchell, Laterre, Pierre-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264912/ https://www.ncbi.nlm.nih.gov/pubmed/34233965 http://dx.doi.org/10.1136/bmjopen-2020-042921 |
Ejemplares similares
-
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial
por: François, Bruno, et al.
Publicado: (2023) -
sTREM-1 is a specific biomarker of TREM-1 pathway activation
por: Jolly, Lucie, et al.
Publicado: (2021) -
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
por: Geven, Christopher, et al.
Publicado: (2019) -
Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
por: Rochwerg, Bram, et al.
Publicado: (2017) -
Rationale, design and methodology of a trial evaluating three strategies designed to improve sedation quality in intensive care units (DESIST study)
por: Walsh, Timothy S, et al.
Publicado: (2016)